ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) - Global Forecast to 2026
Updated on : February 15, 2023
The global ERCP market in terms of revenue was estimated to be worth $1.3 billion in 2021 and is poised to reach $2.0 billion by 2026, growing at a CAGR of 9.6% from 2021 to 2026. The drivers of the market include the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries.
To know about the assumptions considered for the study, Request for Free Sample Report
ERCP Market Dynamics
Driver: rising incidence of cancer
Nowadays, the global incidence of cancer is increasing. According to the WHO, cancer is the second-leading cause of death globally and was responsible for 9.6 million deaths in 2018. According to the American Cancer Society's estimates, about 41,260 new cases of liver cancer and intrahepatic bile duct cancer will be diagnosed in the US in 2022. Liver cancer incidence rates have more than tripled since 1980, while death rates have more than doubled during this time. In 2021, around 60,430 new pancreatic cancer cases will be diagnosed in the US. Every year in the United Kingdom (2016–2018), approximately 10,500 new pancreatic cancer cases and 6,200 new liver cancer cases were diagnosed. Globally, 458,918 new cases of pancreatic cancer were reported in 2018, and 355,317 new cases are estimated to occur until 2040 (GLOBOCAN 2018 estimates). Since ERCP is often used as a diagnostic tool in hepatic, biliary, and pancreatic cancers, the rising incidence of these cancers is directly related to the impact on the ERCP market.
Restraint: high costs of endoscopic retrograde cholangiopancreatography devices
One of the most pertinent restraints on the market is the high cost of ERCP equipment and procedures. The average selling price of a duodenoscope is around USD 31,500 (non-HD) to USD 37,000 (HD). This high price, combined with the long procedure time, makes this unfavorable. Furthermore, according to an expert in the ERCP market, cost is one of the primary reasons why the procedure is not easily accessible and affordable to many small-scale end users who serve a large population, particularly in developing countries.
Opportunity: The growing healthcare sector in emerging economies
Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies globally. According to the World Economic Forum, the emerging economies will account for around one-third of global healthcare expenditure in 2021. More than half of the world's population resides in India and China, owing to which these countries are home to the highest number of patients.
The increasing burden of cancer, rapid improvements in healthcare infrastructure, the rapid growth of medical tourism, and the presence of flexible regulation in these countries encourage players in the endoscopy equipment market to expand their presence in emerging countries.
Several endoscopy equipment manufacturers are currently setting up their facilities in Asia, the Middle East, and Latin America. Karlstrom, for example, has already established manufacturing and R&D facilities in these countries. In addition, market saturation in developed regions, such as North America and Europe, will force manufacturers to focus on emerging markets in the coming years.
By product type segment, the largest share of the ERCP market was occupied by the endotherapy devices segment during the forecast period.
This is due to driving factors such as the growth of minimally invasive surgeries and the increasing prevalence of gastrointestinal conditions.
Under endotherapy devices, sphincterotomes accounted for the largest share of the ERCP market during the forecast period.
the increasing incidence of pancreatic duct and bile duct stones and the increase in the geriatric population (and therefore, an increase in biliary disorders).
To know about the assumptions considered for the study, download the pdf brochure
Asia-Pacific and Latin America are the fastest-growing markets for the ERCP market during the forecast period.
Governments in several Latin American countries focus on improving their respective healthcare systems, and the healthcare sector in Brazil has undergone significant changes, making the country one of the world's most promising and attractive markets. Along with this, Japan's well-developed healthcare system with universal health insurance coverage and the focus of countries such as China and India on healthcare infrastructure improvements to serve large populations of patients with critical illnesses, including cancer and tumors, are driving the market in these regions forward at a rapid pace.
The major players in the global ERCP market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).
Other players in the ERCP market include Hobbs Medical, Inc. (US), STERIS PLC (US), Merit Medical Systems, Inc. (US), TeleMed Systems, Inc. (US), Changzhou Health Microport Medical Device Co., LTD. (China), Medi-Globe GmbH (Germany), Taewoong Medical Co., Ltd. (South Korea), Huger Medical Instrument Co., Ltd. (China), IntroMedic Co., Ltd. (Republic of Korea), SonoScape Medical Corporation (China), Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China), Ottomed (India), Kimberly-Clark Corporation (US), and Shaili Endoscopy (India)
ERCP Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$1.3 billion |
|
Estimated Value by 2026 |
$2.0 billion |
|
Growth Rate |
Poised to grow at a CAGR of 9.6% |
|
Segments covered |
Product, procedure, end-user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
The research report categorizes the ERCP Market into the following segments and subsegments:
By Product
- Endoscopes
-
Endotherapy Devices
- Sphincterotomes
- Lithotripter
- Stents
- Cannulas
- Forceps
- Snares
- Catheters
- Guiding Wires
- Balloons
- Baskets
- Visualization Systems
- Energy Devices
- Others
By Procedure
- Biliary Sphincterotomy
- Biliary Stenting
- Biliary Dialtation
- Pancreatic Sphincterotomy
- Pancreatic Duct Stenting
- Pancreatic Duct Dilatation
End User
- Hospitals
- Ambulatory Surgery Centers & Clinics
- Other End Users
Region
-
North America
- US
- Canada
-
Europe
- France
- Germany
- UK
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Middle East
- Africa
Recent Developments
- In January 2022, Cook Medical (US) launched an endoscopic clipping device, namely Instinct Plus, which is compatible through a duodenoscope, has applications for defect closure, anchoring procedures and prophylactic clipping in the gastrointestinal (GI) tract.
- In May 2021, STERIS PLC (US) acquired Cantel Medical (US) which enabled STERIS Healthcare to expand its product portfolio and cater to customers worldwide.
- In March 2021, Fujifilm Holdings Corporation (Japan) acquired Hitachi, Ltd.’s Diagnostic Imaging-related Business (Japan), adding to the former’s stronghold in the healthcare business.
- In October 2020, Olympus Corporation (Japan) launched two endotherapy devices, StoneMasterV and VorticCatchV, to increase the efficiency in bile duct stone management and retrieval for ERCP announced a partnership with Holberg to develop and distribute the Autoscore algorithm.
Frequently Asked Questions (FAQ):
What is the projected market value of the global ERCP market?
The global market of ERCP is projected to reach USD 2.0 billion.
What is the estimated growth rate (CAGR) of the global ERCP market for the next five years?
The global ERCP market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.6% from 2021 to 2026.
What are the major revenue pockets in the ERCP market currently?
The global ERCP market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share of the ERCP market in 2020. Factors such the increasing prevalence of cancer, high investments by hospitals to purchase new ERCP equipment, and a strong focus on research activities to improve endoscopy techniques.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 29)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 ERCP MARKET
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET)
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION (2020)
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE MARKET (2021–2026)
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 11 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 ASSESSMENT OF IMPACT OF COVID-19 ON ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 13 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 14 MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET OVERVIEW
FIGURE 17 INCREASING INCIDENCE OF CANCER AND THE GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES ARE THE KEY FACTORS DRIVING MARKET GROWTH
4.2 GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY DURING THE FORECAST PERIOD
4.3 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY, BY PRODUCT AND COUNTRY (2020)
FIGURE 19 THE ENDOSCOPES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ERCP MARKET IN NORTH AMERICA FOR 2020
4.4 REGIONAL MIX: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)
FIGURE 20 THE ASIA PACIFIC AND LATIN AMERICA REGIONS ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)
4.5 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 MARKET DYNAMICS: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
5.2.1 MARKET DRIVERS
5.2.1.1 Rising incidence of cancer
FIGURE 23 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF PANCREATIC CANCER, 2020
5.2.1.2 Increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research
TABLE 1 MAJOR DEVELOPMENTS
5.2.1.3 Growing focus on investments by hospitals for advanced endoscopy instruments
TABLE 2 SOME EXAMPLES OF INVESTMENTS BY HOSPITALS FOR ENDOSCOPY INSTRUMENTS
5.2.1.4 Increasing preference for minimally invasive surgeries
FIGURE 24 ENDOSCOPIC GLOBAL MINIMALLY INVASIVE MARKET SIZE (2019-2030)
5.2.2 MARKET RESTRAINTS
5.2.2.1 High costs of endoscopic retrograde cholangiopancreatography devices
5.2.2.2 Development of other procedures like EUS and MRCP
5.2.2.3 Shortage of trained physicians and endoscopists
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 The growing healthcare sector in emerging economies
5.2.3.2 Increasing adoption of single-use endoscopy instruments
5.2.4 MARKET CHALLENGES
5.2.4.1 Product recalls witnessed by major market players
TABLE 3 LIST OF PRODUCT RECALLS
5.2.4.2 Side-effects and infections (like post-ERCP pancreatitis) caused by duodenoscopy products
6 INDUSTRY INSIGHTS (Page No. - 63)
6.1 INTRODUCTION
6.2 TECHNOLOGY TRENDS
6.2.1 ARTIFICIAL INTELLIGENCE IN GI ENDOSCOPY
TABLE 4 AI SYSTEMS AND OTHER RELATED FUNCTIONS
6.2.2 SINGLE-USE ENDOSCOPES
TABLE 5 ADVANTAGES OF DISPOSABLE OR SINGLE-USE ENDOSCOPES OVER REUSABLE ENDOSCOPES
6.2.3 ROBOT-ASSISTED ENDOSCOPES
TABLE 6 ROBOT-ASSISTED ENDOSCOPY PRODUCTS
6.3 INDUSTRY TRENDS
6.3.1 FAVOURABLE REIMBURSEMENT SCENARIO FOR SINGLE-USE DEVICES
6.4 PRICING ANALYSIS
TABLE 7 AVERAGE SELLING PRICE OF FLEXIBLE HD AND NON-HD DUODENOSCOPE (USD)
TABLE 8 US: AVERAGE COST OF ERCP PROCEDURES, 2020 (USD)
6.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
6.6 ECOSYSTEM MAPPING
FIGURE 26 ECOSYSTEM ANALYSIS
6.7 SUPPLY CHAIN ANALYSIS
FIGURE 27 STAKEHOLDERS IN SUPPLY CHAIN
6.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
6.8.1 THREAT OF NEW ENTRANTS
6.8.1.1 High capital requirement
6.8.1.2 High preference for products from well-established brands
6.8.2 THREAT OF SUBSTITUTES
6.8.2.1 Substitute therapies for ERCP procedures
6.8.3 BARGAINING POWER OF SUPPLIERS
6.8.3.1 Presence of several raw material suppliers
6.8.3.2 Supplier switching costs
6.8.4 BARGAINING POWER OF BUYERS
6.8.4.1 Few companies offer premium products at the global level
6.8.5 INTENSITY OF COMPETITIVE RIVALRY
6.8.5.1 Increasing demand for high-quality and innovative products
6.8.5.2 Lucrative growth potential in emerging markets
6.9 REGULATORY ANALYSIS
6.10 PATENT ANALYSIS
6.10.1 PATENT PUBLICATION TRENDS FOR ERCP
FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, 2017–2021
6.10.2 TOP APPLICANTS (COMPANIES) OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS
FIGURE 29 TOP COMPANIES THAT APPLIED FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021
6.10.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY
FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021
6.11 TRADE ANALYSIS
TABLE 10 NUMBER OF EXPORTS AND IMPORTS RELATED TO ERCP EQUIPMENT
6.12 IMPACT OF COVID-19 ON THE ENDOSCOPY EQUIPMENT MARKET
7 ERCP MARKET, BY PRODUCT (Page No. - 78)
7.1 INTRODUCTION
TABLE 11 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
7.2 ENDOSCOPES
7.2.1 THE RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES IS EXPECTED TO DRIVE THE ENDOSCOPES MARKET
TABLE 12 ENDOSCOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 ENDOTHERAPY DEVICES
7.3.1 THESE ARE MINIMALLY INVASIVE DEVICES USED TO TREAT OR DIAGNOSE GI CONDITIONS
TABLE 13 ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 14 ENDOTHERAPY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.2 SPHINCTEROTOME
7.3.2.1 The risk of bleeding post-sphincterotomy is 2%, with 0.1% mortality
TABLE 15 SPHINCTEROTOME MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.3 LITHOTRIPTER
7.3.3.1 Lithotripters are used to pulverize stones into smaller pieces so that they can pass out of a body naturally
TABLE 16 LITHOTRIPTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.4 STENTS
7.3.4.1 Metal stents have higher patency rates and are less expensive than plastic stents
TABLE 17 STENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.5 CANNULAS
7.3.5.1 The success rate of ERCP procedures is directly proportional to cannulation
TABLE 18 CANNULAS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.6 FORCEPS
7.3.6.1 The prevalence of cancer leads to significant demand for biopsy forceps for the collection of tissue samples
TABLE 19 FORCEPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.7 SNARES
7.3.7.1 Snares are commonly used for cold or hot polypectomy
TABLE 20 SNARES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.8 CATHETERS
7.3.8.1 Catheters inject a contrast medium for the visualization of internal tissues
TABLE 21 CATHETERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.9 GUIDING WIRES
7.3.9.1 The most used guidewires in ERCP come in three different diameters: 0.018, 0.025, and 0.035 inches
TABLE 22 GUIDING WIRES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.10 BALLOONS
7.3.10.1 Balloon endoscopy involves balloons that inflate and deflate to pinch together the walls of the GI tract
TABLE 23 BALLOONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.11 BASKETS
7.3.11.1 Baskets are commonly used instruments for the removal of bile duct stones in ERCP
TABLE 24 BASKETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 VISUALIZATION SYSTEMS
7.4.1 VISUALIZATIONS SYSTEMS HAVE APPLICATIONS ACROSS ALL ERCP PROCEDURES
TABLE 25 VISUALIZATION SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 ENERGY DEVICES
7.5.1 ENERGY DEVICES CAN BE MONOPOLAR OR BIPOLAR
TABLE 26 ENERGY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 OTHERS
TABLE 27 ERCP ACCESSORIES AND DESCRIPTIONS
TABLE 28 OTHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 ERCP MARKET, BY PROCEDURE (Page No. - 96)
8.1 INTRODUCTION
TABLE 29 MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
8.2 BILIARY SPHINCTEROTOMY
8.2.1 INCREASING INCIDENCE RATES OF SOD TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 30 MARKET FOR BILIARY SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 BILIARY DILATATION
8.3.1 HIGH-CHOLESTEROL DIETS AND OBESITY ARE THE KEY CAUSES OF GALLSTONES, THUS DRIVING THE UPTAKE OF BILIARY DILATATION PROCEDURES
TABLE 31 MARKET FOR BILIARY DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 BILIARY STENTING
8.4.1 THE RISING PREVALENCE OF GALLBLADDER DISEASES IN THE GROWING GERIATRIC POPULATION IS EXPECTED TO PROPEL THE DEMAND FOR BILIARY STENTS
TABLE 32 MARKET FOR BILIARY STENTING, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 PANCREATIC SPHINCTEROTOMY
8.5.1 THE RISING INCIDENCE OF PANCREATIC CANCER IS EXPECTED TO DRIVE THE DEMAND FOR THIS PROCEDURE
TABLE 33 MARKET FOR PANCREATIC SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 PANCREATIC DUCT DILATATION
8.6.1 BALLOON DILATION ALONG WITH ENDOSCOPIC SPHINCTEROTOMY IS THE PREFERRED PROCEDURE FOR STONE REMOVAL
TABLE 34 MARKET FOR PANCREATIC DUCT DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)
8.7 PANCREATIC DUCT STENTING
8.7.1 PANCREATIC DUCT STENTING IS THE TREATMENT OF CHOICE FOR CHRONIC PANCREATIC DISORDERS
TABLE 35 MARKET FOR PANCREATIC DUCT STENTING, BY COUNTRY, 2019–2026 (USD MILLION)
9 ERCP MARKET, BY END USER (Page No. - 104)
9.1 INTRODUCTION
TABLE 36 MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 HOSPITALS
9.2.1 INCREASING INVESTMENTS BY GOVERNMENT ORGANISATIONS BOOST THE ADOPTION OF ERCP BY THIS END-USER SEGMENT
TABLE 37 MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 AMBULATORY SURGERY CENTERS/CLINICS
9.3.1 AMBULATORY SURGERY CENTERS PROVIDE OUTPATIENT ECRP PROCEDURES THROUGH EFFICIENT OPERATIONS
TABLE 38 MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 OTHER END USERS
TABLE 39 MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
10 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION (Page No. - 109)
10.1 INTRODUCTION
FIGURE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 40 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INDUSTRY, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: MARKET SNAPSHOT
TABLE 41 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The large market in the US is mainly driven by high healthcare spending in the country and the increasing incidence of cancer
TABLE 46 MEDICARE NATIONAL AVERAGE COVERAGE FOR OUTPATIENT PROCEDURES, 2020
TABLE 47 LIST OF DEVICES THAT RECEIVED FDA APPROVALS BETWEEN 2018 AND 2021
TABLE 48 US: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 49 US: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 50 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 51 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High costs of endoscopic retrograde cholangiopancreatography to restrain the market growth in Canada
TABLE 52 INCIDENCE ESTIMATES BY CANCER TYPE (CANADA)
TABLE 53 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 54 CANADA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 55 CANADA: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 56 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 57 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 59 EUROPE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 60 EUROPE: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany’s rising geriatric population is one of the key drivers for the ERCP market
TABLE 62 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 63 GERMANY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 GERMANY: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 65 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Investments by hospitals to purchase new & advanced ERCP equipment is expected to propel market growth in the UK
TABLE 66 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 67 UK: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 UK: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 69 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 High healthcare expenditure is expected to support the growth of the ERCP market in France
TABLE 70 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 71 FRANCE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 FRANCE: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 73 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 SPAIN
10.3.4.1 Increasing prevalence of cardiovascular diseases in Spain to stimulate the market growth for endoscopes
TABLE 74 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 75 SPAIN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 SPAIN: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 77 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Rising government initiatives for the adoption of advanced medical equipment to drive the market growth for ERCP equipment & procedures in Italy
TABLE 78 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 79 ITALY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 ITALY: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 81 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE (ROE)
TABLE 82 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 83 ROE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 ROE: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 85 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT
TABLE 86 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 ASIA PACIFIC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 88 ASIA PACIFIC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 ASIA PACIFIC: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Supportive medical device reimbursement policies to drive the market growth for ERCP in Japan
TABLE 91 JAPAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 92 JAPAN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 JAPAN: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 94 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Large patient population and the strong need for healthcare infrastructure improvements to drive the market growth in China
TABLE 95 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 96 CHINA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 CHINA: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 98 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Favorable government initiatives for improvements in healthcare infrastructure to support the market growth for ERCP in India
TABLE 99 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 100 INDIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 INDIA: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 102 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 The high number of cancer rates in Australia is expected to drive the demand for endoscopy instruments
TABLE 103 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 104 AUSTRALIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 AUSTRALIA: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 106 AUSTRALIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC (ROAPAC)
TABLE 107 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 108 ROAPAC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 ROAPAC: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 110 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 THE GOVERNMENTS IN MANY LATIN AMERICAN COUNTRIES ARE FOCUSED ON IMPROVING HEALTHCARE INFRASTRUCTURE, AND IN TURN, THE ADOPTION OF ERCP IS EXPECTED TO RISE
TABLE 111 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 112 LATIN AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 114 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.2 MIDDLE EAST
10.5.2.1 Healthcare infrastructural advancements are expected to create the requirement for advanced hospital equipment such as ERCP in the region
TABLE 115 MIDDLE EAST: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 116 MIDDLE EAST: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 118 MIDDLE EAST: MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.3 AFRICA
10.5.3.1 High prevalence of target diseases and initiatives to strengthen endoscopic services in healthcare organizations to propel market growth
TABLE 119 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 120 AFRICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 122 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 158)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
11.4 COMPETITIVE BENCHMARKING
TABLE 123 FOOTPRINT OF COMPANIES IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
TABLE 124 PRODUCT AND SERVICE: COMPANY FOOTPRINT (25 COMPANIES)
TABLE 125 END USER: COMPANY FOOTPRINT (25 COMPANIES)
TABLE 126 REGION: COMPANY FOOTPRINT (26 COMPANIES)
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STAR
11.5.2 EMERGING LEADER
11.5.3 PERVASIVE PLAYER
11.5.4 PARTICIPANT
FIGURE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES
11.6.1 PROGRESSIVE COMPANY
11.6.2 DYNAMIC COMPANY
11.6.3 STARTING BLOCK
11.6.4 RESPONSIVE COMPANY
FIGURE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)
11.7 MARKET RANKING ANALYSIS
FIGURE 37 ERCP MARKET RANKING ANALYSIS, BY PLAYER, 2020
FIGURE 38 ENDOTHERAPY DEVICES MARKET RANKING ANALYSIS, BY PLAYER, 2020
11.8 COMPETITIVE SCENARIO
TABLE 127 PRODUCT LAUNCHES & APPROVALS, 2019–2021
TABLE 128 DEALS, 2019–2021
12 COMPANY PROFILES (Page No. - 173)
(Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made)*
12.1 KEY PLAYERS
12.1.1 OLYMPUS CORPORATION
TABLE 129 OLYMPUS CORPORATION: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2020)
12.1.2 CONMED CORPORATION
TABLE 130 CONMED CORPORATION: BUSINESS OVERVIEW
FIGURE 40 COMPANY SNAPSHOT: CONMED CORPORATION (2020)
12.1.3 AMBU A/S
TABLE 131 AMBU A/S: BUSINESS OVERVIEW
FIGURE 41 COMPANY SNAPSHOT: AMBU A/S (2020)
12.1.4 BOSTON SCIENTIFIC CORPORATION
TABLE 132 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2020)
12.1.5 JOHNSON & JOHNSON
TABLE 133 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 43 COMPANY SNAPSHOT: JOHNSON & JOHNSON (2020)
12.1.6 FUJIFILM HOLDINGS CORPORATION
TABLE 134 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 44 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2020)
12.1.7 MEDTRONIC, PLC
TABLE 135 MEDTRONIC, PLC: BUSINESS OVERVIEW
FIGURE 45 COMPANY SNAPSHOT: MEDTRONIC, PLC (2020)
12.1.8 KARL STORZ SE & CO. KG
TABLE 136 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW
12.1.9 COOK MEDICAL
TABLE 137 COOK MEDICAL: BUSINESS OVERVIEW
12.1.10 HOYA CORPORATION
TABLE 138 HOYA CORPORATION: BUSINESS OVERVIEW
FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2020)
12.1.11 B. BRAUN MELSUNGEN AG
TABLE 139 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 47 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG (2020)
12.1.12 HOBBS MEDICAL, INC.
TABLE 140 HOBBS MEDICAL, INC.: BUSINESS OVERVIEW
12.1.13 STERIS PLC
FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2020)
TABLE 141 STERIS PLC: BUSINESS OVERVIEW
12.1.14 MERIT MEDICAL SYSTEMS, INC.
TABLE 142 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 49 COMPANY SNAPSHOT: MERIT MEDICAL SYSTEMS, INC. (2020)
12.1.15 TELEMED SYSTEMS, INC.
TABLE 143 TELEMED SYSTEMS, INC.: BUSINESS OVERVIEW
12.1.16 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.
TABLE 144 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW
12.1.17 MEDI-GLOBE GMBH
TABLE 145 MEDI-GLOBE GMBH: BUSINESS OVERVIEW
12.1.18 TAEWOONG MEDICAL CO., LTD.
TABLE 146 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW
12.1.19 HUGER MEDICAL INSTRUMENT CO., LTD.
TABLE 147 HUGER MEDICAL INSTRUMENT CO., LTD..: BUSINESS OVERVIEW
12.1.20 INTROMEDIC CO., LTD.
TABLE 148 INTROMEDIC CO., LTD.: BUSINESS OVERVIEW
FIGURE 50 COMPANY SNAPSHOT: INTROMEDIC CO., LTD. (2020)
12.1.21 SONOSCAPE MEDICAL CORP.
TABLE 149 SONOSCAPE MEDICAL CORP.: BUSINESS OVERVIEW
FIGURE 51 COMPANY SNAPSHOT: SONOSCAPE MEDICAL CORP (2020)
12.2 OTHER PLAYERS
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 230)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the endoscopic retrograde cholangiopancreatography market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the endoscopic retrograde cholangiopancreatography market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the endoscopic retrograde cholangiopancreatography market was arrived at after data triangulation from two different approaches, as mentioned below.
Approach to calculate the revenue of different players in the endoscopic retrograde cholangiopancreatography market
The size of the global endoscopic retrograde cholangiopancreatography market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global endoscopic retrograde cholangiopancreatography market was derived.
Approach to derive the market size and estimate market growth
The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.
Data Triangulation
After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Objectives of the Study
- To define, describe, and forecast the endoscopic retrograde cholangiopancreatography market based on product, procedure, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall endoscopic retrograde cholangiopancreatography market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players in the market and comprehensively analyze their market shares and core competencies
- To forecast the size of the market segments with respect to six main regions, namely, North America, Asia Pacific, Europe, Latin America, Middle East, and Africa.
- To track and analyze competitive developments such as new product launches, agreements, collaborations, and expansions.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific endoscopic retrograde cholangiopancreatography market into South Korea, New Zealand, and other countries
- Further breakdown of the Rest of Europe endoscopic retrograde cholangiopancreatography market into Belgium, Russia, the Netherlands, Switzerland, and other countries
- Further breakdown of the Latin America endoscopic retrograde cholangiopancreatography market into the Brazil, Mexico, Argentina, and other countries.
Generating Response ...
Growth opportunities and latent adjacency in ERCP Market
What are the challenges in Endoscopic Retrograde Cholangiopancreatography Market?
What are the key trends impacting the Endoscopic Retrograde Cholangiopancreatography Market?
What will be the future perspectives in Endoscopic Retrograde Cholangiopancreatography Market?
What will be the key challenges for business in ERCP industry in the future?